Abstract
A wealth of data in animal models indicates that type 1A diabetes results from T cell-mediated specific destruction of islet β cells. There is evidence for the NOD mouse model that insulin is the primary autoantigen and a specific insulin peptide B:9-23 is central to pathogenesis. It is also now possible to predict the development of type 1A (immune mediated) diabetes for the great majority of individuals with a combination of genetic, immunological and metabolic parameters. Such prediction is possible because of the chronic nature of the autoimmunity and loss of β cell function that precedes the disease. Given the ability to predict type 1A diabetes trials at all stages of the disorder to prevent β cell destruction are now possible.
| Original language | English |
|---|---|
| Title of host publication | Defining Optimal Immunotherapies for Type 1 Diabetes |
| Pages | 85-94 |
| Number of pages | 10 |
| Publication status | Published - 21 Nov 2008 |
Publication series
| Name | Novartis Foundation Symposium |
|---|---|
| Volume | 292 |
| ISSN (Print) | 1528-2511 |
Fingerprint Dive into the research topics of 'Type 1 diabetes: Chronic progressive autoimmune disease'. Together they form a unique fingerprint.
Cite this
Zhang, L., Gianani, R., Nakayama, M., Liu, E., Kobayashi, M., Baschal, E., Yu, L., Babu, S., Dawson, A., Johnson, K., Jahromi, M., Aly, T., Fain, P., Barker, J., Rewers, M., & Eisenbarth, G. S. (2008). Type 1 diabetes: Chronic progressive autoimmune disease. In Defining Optimal Immunotherapies for Type 1 Diabetes (pp. 85-94). (Novartis Foundation Symposium; Vol. 292).